Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Abstract Larotrectinib is an orally administered drug and the first and only selective pan-tropomyosin receptor kinase (TRK) inhibitor in clinical development to treat cancer patients harboring a neurotrophic receptor tyrosine kinase gene fusion. In this study, an analytical method to quantify the T...

Full description

Bibliographic Details
Main Authors: Yoon-Jee Chae, Yoo-Kyung Song, Song-Hee Chae, Min Ju Kim, Jong Soon Kang, Jae-Young Lee, Tae-Sung Koo, Kyeong-Ryoon Lee
Format: Article
Language:English
Published: SpringerOpen 2020-06-01
Series:Journal of Analytical Science and Technology
Subjects:
Larotrectinib
TRK inhibitor
Pharmacokinetics
Mass spectrometry
Online Access:http://link.springer.com/article/10.1186/s40543-020-00219-5

Internet

http://link.springer.com/article/10.1186/s40543-020-00219-5

Similar Items